Literature DB >> 27031213

Discovery of a ring-opened derivative of 3-n-butylphthalide bearing NO/H2S-donating moieties as a potential anti-ischemic stroke agent.

Wei Yin1, Li Lan2, Zhangjian Huang1, Jing Ji2, Jiangen Fang1, Xiaoli Wang3, Hui Ji2, Sixun Peng1, Jinyi Xu2, Yihua Zhang4.   

Abstract

To search for novel anti-ischemic stroke agents with higher potency than a known drug 3-n-butylphthalide (NBP), a series of ring-opened derivatives of NBP bearing both nitric oxide (NO) and hydrogen sulfide (H2S)-donating moieties (NO/H2S-NBP) (8a-8o) were designed, synthesized, and biologically evaluated. The most active compound 8d was more potent than NBP and the corresponding H2S-NBP 10 or NO-NBP 13 in inhibition of the ADP-induced platelet aggregation in vitro. In addition, 8d produced moderate levels of NO and H2S, which could be beneficial for improving cardiovascular and cerebral circulation. More importantly, in a rat model of transient focal cerebral ischemia, oral treatment with 8d improved neurobehavioral function, reduced the infarct brain size and brain-water content, and enhanced the levels of brain antioxidant SOD, GSH and GSH-Px but diminished the level of oxidant MDA. These protective effects of 8d against the ischemia/reperfusion (I/R)-related brain damage were greater than that of NBP, suggesting that 8d may be a promising agent for further investigation.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-platelet aggregation; Hydrogen sulfide; Ischemic stroke; Nitric oxide

Mesh:

Substances:

Year:  2016        PMID: 27031213     DOI: 10.1016/j.ejmech.2016.03.044

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

Review 1.  New insights into targeting mitochondria in ischemic injury.

Authors:  Jingjing Jia; Haiqiang Jin; Ding Nan; Weiwei Yu; Yining Huang
Journal:  Apoptosis       Date:  2021-03-09       Impact factor: 4.677

Review 2.  International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors.

Authors:  Csaba Szabo; Andreas Papapetropoulos
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

3.  Preclinical Pharmacokinetics, Tissue Distribution, and Plasma Protein Binding of Sodium (±)-5-Bromo-2-(α-Hydroxypentyl) Benzoate (BZP), an Innovative Potent Anti-ischemic Stroke Agent.

Authors:  Xin Tian; Hong-Meng Li; Jing-Yao Wei; Bing-Jie Liu; Yu-Hai Zhang; Gao-Ju Wang; Jun-Biao Chang; Hai-Ling Qiao
Journal:  Front Pharmacol       Date:  2016-08-18       Impact factor: 5.810

Review 4.  A Review of Recent Advances in Neuroprotective Potential of 3-N-Butylphthalide and Its Derivatives.

Authors:  Idriss Ali Abdoulaye; Yi Jing Guo
Journal:  Biomed Res Int       Date:  2016-12-08       Impact factor: 3.411

5.  NOSH-NBP, a Novel Nitric Oxide and Hydrogen Sulfide- Releasing Hybrid, Attenuates Ischemic Stroke-Induced Neuroinflammatory Injury by Modulating Microglia Polarization.

Authors:  Jing Ji; Pengjun Xiang; Tingting Li; Li Lan; Xiaole Xu; Guo Lu; Hui Ji; Yihua Zhang; Yunman Li
Journal:  Front Cell Neurosci       Date:  2017-05-26       Impact factor: 5.505

6.  Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction.

Authors:  Xuewen Wo; Jinyan Han; Jiajia Wang; Xinmin Wang; Xiaoying Liu; Zhonggong Wang
Journal:  Pak J Med Sci       Date:  2020 May-Jun       Impact factor: 1.088

7.  Efficacy of sequential N-butylphthalide therapy on psychiatric and behavioral functions in acute ischemic stroke.

Authors:  Le Yang; Hui Li; Yanzhi Wu; Hongdan Zhang; Jieqiong Du; Yankun Chen
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

8.  The Efficacy of N-Butylphthalide and Dexamethasone Combined with Hyperbaric Oxygen on Delayed Encephalopathy After Acute Carbon Monoxide Poisoning.

Authors:  Jiefang Zhang; Yuewen Guo; Wenyao Li; Guangli Li; Yankun Chen
Journal:  Drug Des Devel Ther       Date:  2020-04-02       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.